Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Pfizer ticks up on Street-beating Q1, lessens full-year guidance

By Sean Whooley | May 3, 2022

PfizerPfizer (NYSE:PFE) shares rose today on first-quarter financial results that came in ahead of the consensus forecast.

The New York-based pharmaceutical company posted profits of $7.9 billion, or $1.37 per share, on sales of $25.7 billion for the three months ended April 3, 2022, for a 61.2% bottom-line gain on sales growth of 76.8%.

Adjusted to exclude one-time items, earnings per share were $1.62, 15¢ ahead of Wall Street, where analysts were looking for sales of $23.9 billion.

Pfizer reported 82% operational growth overall, while the company registered operational growth of 2% when excluding its Comirnaty COVID-19 vaccine and Paxlovid oral COVID-19 treatment. Comirnaty sales grew by $10.2 billion to $13.2 billion in the quarter, while Paxlovid contributed $1.5 billion to global sales, driven by the U.S. launch of the treatment in December 2021 and following international launches.

“I am very proud of our performance this quarter, both from a financial perspective and from the standpoint of trying to be a force for good in the world,” Pfizer Chair and CEO Albert Bourla said in a news release. “We continue to supply the world with Comirnaty, which remains a critical tool for helping patients and societies avoid the worst impacts of the COVID-19 pandemic, and we are on track to fulfill our commitment to deliver at least 2 billion doses to low- and middle-income countries in 2021 and 2022, including at least 1 billion doses this year. In addition, we are delivering on our production commitments for Paxlovid, which is already having a profound impact on the lives of patients.”

Pfizer said it now expects to log adjusted EPS of between $6.25 and $6.45, reflecting a 10¢ drop at each end from the previously projected range of $6.35 to $6.55. The company’s revenue guidance remains unchanged at 27% operational growth from 2021 revenues at the midpoint.

The company projects approximately $32 billion in Comirnaty revenues and $22 billion in Paxlovid revenues for the full year.

PFE shares were up 1.7% at $49.22 per share in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was practically unchanged.


Filed Under: Drug Discovery, Drug Discovery and Development, Immunology, Infectious Disease
Tagged With: coronavirus, covid-19, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Black Diamond Therapeutics
Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50